Journal article icon

Journal article

What to do with diabetes therapies when HbA1c lowering is inadequate: add, switch, or continue? A MASTERMIND study

Abstract:

BACKGROUND:It is unclear what to do when people with type 2 diabetes have had no or a limited glycemic response to a recently introduced medication. Intra-individual HbA1c variability can obscure true response. Some guidelines suggest stopping apparently ineffective therapy, but no studies have addressed this issue. METHODS:In a retrospective cohort analysis using the UK Clinical Practice Research Datalink (CPRD), we assessed the outcome of 55,530 patients with type 2 diabetes starting their ...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Publisher copy:
10.1186/s12916-019-1307-8

Authors


More by this author
Role:
Author
ORCID:
0000-0002-6833-9399

Contributors

Institution:
University of Oxford
Division:
MSD
Department:
Primary Care Health Sciences
Role:
Collaborator
More from this funder
Name:
Wellcome Trust
Grant:
102820/Z/13/Z
More from this funder
Name:
Medical Research Foundation
Grant:
MR/N00633X/1
Publisher:
BioMed Central
Journal:
BMC Medicine More from this journal
Volume:
17
Article number:
79
Publication date:
2019-04-12
Acceptance date:
2019-03-13
DOI:
EISSN:
1741-7015
Pmid:
30979373
Language:
English
Keywords:
Pubs id:
pubs:995120
UUID:
uuid:a0532f54-62d7-4651-a3e7-5382b24e46b3
Local pid:
pubs:995120
Source identifiers:
995120
Deposit date:
2019-06-11

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP